Bolt Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary

Bolt Biotherapeutics

08/08/2023 13:00

* Bolt Biotherapeutics Inc  BOLT.OQ  reported a quarterly
adjusted
loss of 48 cents​​ per share for the quarter ended in June. The
mean expectation of six analysts for the quarter was for a loss
of 49 cents per share.
    * Revenue rose 2.9% to $1.43 million from a year ago;
analysts
expected $1.90 million. 
    * Bolt Biotherapeutics Inc's reported EPS for the quarter
was a
loss of 48 cents​.
    * The mean earnings estimate of analysts had risen by
about 2.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Bolt Biotherapeutics Inc shares had risen by 0.8% this
quarter and lost 0.8% so far this year.
    * The company reported a quarterly loss of $18.06 million.
    * Wall Street's median 12-month price target for Bolt
Biotherapeutics Inc is $4.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 11:59 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.49          -0.48          Beat
 Mar. 31 2023      -0.51          -0.45          Beat
 Dec. 31 2022      -0.60          -0.53          Beat
 Sep. 30 2022      -0.56          -0.58          Missed